Telo Genomics Corp. (TELO.V)
CAD 0.12
(0.0%)
CAD 0.12
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.71 Million CAD | 3.63% |
| 2022 | -2.82 Million CAD | -33.66% |
| 2021 | -2.11 Million CAD | -96.56% |
| 2020 | -1.07 Million CAD | 11.64% |
| 2019 | -1.21 Million CAD | -15.34% |
| 2018 | -1.05 Million CAD | 76.61% |
| 2017 | -4.5 Million CAD | 51.57% |
| 2016 | -9.3 Million CAD | -12555.13% |
| 2015 | -73.49 Thousand CAD | 34.29% |
| 2014 | -111.84 Thousand CAD | -144.67% |
| 2013 | -45.71 Thousand CAD | 62.82% |
| 2012 | -122.96 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -615.04 Thousand CAD | 26.25% |
| 2023 Q1 | -672.54 Thousand CAD | 21.33% |
| 2023 Q4 | -598.13 Thousand CAD | 2.75% |
| 2023 Q2 | -833.97 Thousand CAD | -24.0% |
| 2022 Q3 | -710.88 Thousand CAD | -11.21% |
| 2022 Q4 | -854.87 Thousand CAD | -20.25% |
| 2022 FY | -2.82 Million CAD | -33.66% |
| 2022 Q1 | -615.8 Thousand CAD | 5.73% |
| 2022 Q2 | -639.21 Thousand CAD | -3.8% |
| 2021 Q1 | -478.94 Thousand CAD | -66.2% |
| 2021 FY | -2.11 Million CAD | -96.56% |
| 2021 Q4 | -653.23 Thousand CAD | -26.85% |
| 2021 Q3 | -514.98 Thousand CAD | -11.16% |
| 2021 Q2 | -463.29 Thousand CAD | 3.27% |
| 2020 Q4 | -288.17 Thousand CAD | 6.92% |
| 2020 FY | -1.07 Million CAD | 11.64% |
| 2020 Q3 | -309.6 Thousand CAD | -13.07% |
| 2020 Q2 | -273.81 Thousand CAD | -38.24% |
| 2020 Q1 | -198.07 Thousand CAD | 35.52% |
| 2019 Q1 | -138.64 Thousand CAD | 24.57% |
| 2019 FY | -1.21 Million CAD | -15.34% |
| 2019 Q4 | -307.16 Thousand CAD | 4.44% |
| 2019 Q3 | -321.42 Thousand CAD | 42.71% |
| 2019 Q2 | -561.04 Thousand CAD | -304.67% |
| 2018 Q2 | -176.02 Thousand CAD | 69.61% |
| 2018 Q1 | -579.25 Thousand CAD | 42.06% |
| 2018 FY | -1.05 Million CAD | 76.61% |
| 2018 Q4 | -183.79 Thousand CAD | -60.59% |
| 2018 Q3 | -114.44 Thousand CAD | 34.98% |
| 2017 Q4 | -999.79 Thousand CAD | -13.22% |
| 2017 Q1 | -1.06 Million CAD | 50.69% |
| 2017 FY | -4.5 Million CAD | 51.57% |
| 2017 Q2 | -1.55 Million CAD | -45.41% |
| 2017 Q3 | -883.08 Thousand CAD | 43.15% |
| 2016 Q4 | -2.16 Million CAD | -0.14% |
| 2016 Q3 | -2.16 Million CAD | -34.69% |
| 2016 Q2 | -1.6 Million CAD | 52.23% |
| 2016 Q1 | -3.36 Million CAD | -17508.11% |
| 2016 FY | -9.3 Million CAD | -12555.13% |
| 2015 Q2 | -60.91 Thousand CAD | -2845.25% |
| 2015 Q1 | 2219.00 CAD | 126.58% |
| 2015 FY | -73.49 Thousand CAD | 34.29% |
| 2015 Q4 | -19.09 Thousand CAD | 58.35% |
| 2015 Q3 | -45.84 Thousand CAD | 24.74% |
| 2014 Q3 | -6445.00 CAD | 63.81% |
| 2014 Q2 | -17.8 Thousand CAD | -45.55% |
| 2014 FY | -111.84 Thousand CAD | -144.67% |
| 2014 Q1 | -12.23 Thousand CAD | 53.36% |
| 2014 Q4 | -8348.00 CAD | -29.53% |
| 2013 Q3 | -55.57 Thousand CAD | -163.24% |
| 2013 Q1 | -4498.00 CAD | 64.2% |
| 2013 FY | -45.71 Thousand CAD | 62.82% |
| 2013 Q4 | -26.23 Thousand CAD | 52.79% |
| 2013 Q2 | -21.11 Thousand CAD | -369.32% |
| 2012 Q4 | -12.56 Thousand CAD | -66.59% |
| 2012 Q3 | -7542.00 CAD | 45.85% |
| 2012 Q2 | -13.92 Thousand CAD | -86.32% |
| 2012 FY | -122.96 Thousand CAD | 0.0% |
| 2012 Q1 | -7476.00 CAD | 41.98% |
| 2011 Q3 | -88.67 Thousand CAD | 0.0% |
| 2011 Q4 | -12.88 Thousand CAD | 85.47% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Avricore Health Inc. | -583.26 Thousand CAD | -366.065% |